[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490394":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":19,"locations":27,"responsibleParty":52,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Pulmonary Arterial Hypertension (Group I)",null,"Group I Pulmonary Arterial Hypertension associated with Connective Tissue Diseases",{"label":13,"type":10,"description":14,"interventionNames":10},"Pulmonary Arterial Hypertension (Group IV)","Group IV Pulmonary Arterial Hypertension associated with Connective Tissue Diseases",[16],{"name":17,"affiliation":5,"role":18},"Jose Luis Hernandez Oropeza, PhD","PRINCIPAL_INVESTIGATOR",[20,24],{"name":17,"role":21,"phone":22,"phoneExt":10,"email":23},"CONTACT","+52 55 5487 0900","elinternista@hotmail.com",{"name":25,"role":21,"phone":22,"phoneExt":10,"email":26},"Jose de Jesus Rodriguez Andoney, M.Sc.","andoneyjjr@hotmail.com",[28],{"facility":29,"status":30,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán","RECRUITING","Mexico City","14080","Mexico","MX",{"type":36,"coordinates":37},"Point",[38,39],-99.12766,19.42847,{"lat":39,"lon":38},[42,45,46,48,50],{"name":17,"role":21,"phone":43,"phoneExt":44,"email":23},"55 5487 0900","2209",{"name":17,"role":18,"phone":10,"phoneExt":10,"email":10},{"name":25,"role":47,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"name":49,"role":47,"phone":10,"phoneExt":10,"email":10},"Alice Yanine Ramirez Lozano, MD",{"name":51,"role":47,"phone":10,"phoneExt":10,"email":10},"Eduardo Rivero Sigarroa, MD",{"type":18,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jose Luis Hernandez Oropeza","Head of the Pulmonary Hypertension Clinic","100490394","registry-of-pulmonary-arterial-hypertension-associated-with-connective-tissue-diseases-reconnective-100490394",false,"NCT05665556","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)","REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán","RECONNECTIVE","Inclusion Criteria:\n\n* Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD)\n* Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation\u002Fperfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy.\n* Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology.\n* Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \\>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units\n\nExclusion Criteria:\n\n* Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).","ALL","18 Years",{"count":66,"type":67},170,"ESTIMATED","5 Years","OBSERVATIONAL","The RECONNECTIVE Registry is an observational single center study, focused on the subgroup of precapillary pulmonary hypertension related to connective tissue diseases. All patients will have hemodynamic confirmation by right heart catheterization and will be follow-up for at least 5 years from admission. All patients diagnosed with Group I Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) and Group IV Pulmonary Hypertension (PH) with CTD will be included. The purpose of the registry is to learn and understand the clinical outcomes and natural history of the pulmonary arterial hypertension in this subgroup of patients to improve the medical care and treatment.",[72,73],"Pulmonary Arterial Hypertension","Connective Tissue Diseases",[72,75],"Connective Tissue Disease","2023-06-27",{"date":78,"type":79},"2023-06-29","ACTUAL",{"date":81,"type":79},"2022-12-15",{"date":83,"type":67},"2027-12",{"name":5,"class":6},1]